SKI Market

A+| A| A-|

Indian Indices

Sensex

71,947.55 -1,635.67
( -2.22%)

Global Indices

Nasdaq

45,242.12 54.47
(0.12%)

Dow Jones

6,365.58 -24.27
(-0.38%)

Hang Seng

51,264.29 -621.56
(-1.20%)

Nikkei 225

10,176.45 48.49
(0.48%)

Forex

USD-INR

94.53 0.44
(0.47%)

EUR-INR

108.77 0.13
(0.12%)

GBP-INR

125.32 -0.25
(-0.20%)

JPY-INR

0.59 0.00
(-0.02%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Bal Pharma Ltd

Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln

BSE Code

ISIN Demat

Book Value()

524824

INE083D01012

62.7662681

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

BALPHARMA

11.06

95.75

EPS(TTM)

Face Value()

Div & Yield %

5.44

Back

Ajmera Realty & Infra India consolidated net profit declines 14.09% in the September 2025 quarter

Nov 06,2025

Net profit of Ajmera Realty & Infra India declined 14.09% to Rs 30.37 crore in the quarter ended September 2025 as against Rs 35.35 crore during the previous quarter ended September 2024. Sales rose 9.56% to Rs 219.04 crore in the quarter ended September 2025 as against Rs 199.92 crore during the previous quarter ended September 2024.

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	219.04	199.92	10
OPM %	26.47	30.20	-
PBDT	43.65	47.04	-7
PBT	42.80	46.53	-8
NP	30.37	35.35	-14

71,947.55 -1,635.67 ( -2.22%)

45,242.12 54.47 (0.12%)

6,365.58 -24.27 (-0.38%)

51,264.29 -621.56 (-1.20%)

10,176.45 48.49 (0.48%)

94.53 0.44 (0.47%)

108.77 0.13 (0.12%)

125.32 -0.25 (-0.20%)

0.59 0.00 (-0.02%)